Effect of DPP-IV Inhibitors on Glycemic Variability in Patients with T2DM: A Systematic Review and Meta-Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Subin | - |
dc.contributor.author | Lee, Heeyoung | - |
dc.contributor.author | Kim, Yoonhye | - |
dc.contributor.author | Kim, EunYoung | - |
dc.date.available | 2020-02-27T02:22:19Z | - |
dc.date.created | 2020-02-04 | - |
dc.date.issued | 2019-09-16 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/1007 | - |
dc.description.abstract | Glycemic variability (GV) has been an emerging target for preventing complications related to type 2 diabetes. For reducing GV, DPP-IV inhibitors have shown effectiveness compared to other oral antihyperglycemic drugs (OADs), but systematic evaluation has yet to be existed. A systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to evaluate the effect of DPP-IV inhibitors compared with other OADs, on GV as measured by mean amplitude of glycemic excursions (MAGE). Searches were conducted using Pubmed, EM BASE, and the Cochrane Library, from which eligible studies were retrieved; seven RCTs were included in the analysis. DPP-IV inhibitors were found to significantly reduce MAGE compared to other OADs (mean difference = -14.61; 95% CI = -19.00 to -10.21; p < 0.0001) without significant heterogeneity among sulfonylureas (mean difference = -14.93; 95% CI = -21.60 to -8.26; p < 0.0001). Initial combination therapy with DPP-IV inhibitors more effectively reduced MAGE than stepwise add-on therapies (p = 0.006), although no differences in MAGE were found based on HbA1c values. These findings indicate that DPP-IV inhibitors are promising alternatives for reducing GV in type 2 diabetes patients. However, further studies utilizing larger numbers of patients and longer-term follow-ups are needed. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.subject | DIPEPTIDYL PEPTIDASE-4 INHIBITORS | - |
dc.subject | ACUTE GLUCOSE FLUCTUATIONS | - |
dc.subject | TYPE-2 DIABETES ROLE | - |
dc.subject | OXIDATIVE STRESS | - |
dc.subject | METFORMIN | - |
dc.subject | SULFONYLUREA | - |
dc.subject | COMPLICATIONS | - |
dc.subject | VILDAGLIPTIN | - |
dc.subject | INFLAMMATION | - |
dc.subject | GLIMEPIRIDE | - |
dc.title | Effect of DPP-IV Inhibitors on Glycemic Variability in Patients with T2DM: A Systematic Review and Meta-Analysis | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000485861500021 | - |
dc.identifier.doi | 10.1038/s41598-019-49803-9 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, v.9 | - |
dc.identifier.scopusid | 2-s2.0-85072291865 | - |
dc.citation.title | SCIENTIFIC REPORTS | - |
dc.citation.volume | 9 | - |
dc.contributor.affiliatedAuthor | Lee, Heeyoung | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | DIPEPTIDYL PEPTIDASE-4 INHIBITORS | - |
dc.subject.keywordPlus | ACUTE GLUCOSE FLUCTUATIONS | - |
dc.subject.keywordPlus | TYPE-2 DIABETES ROLE | - |
dc.subject.keywordPlus | OXIDATIVE STRESS | - |
dc.subject.keywordPlus | METFORMIN | - |
dc.subject.keywordPlus | SULFONYLUREA | - |
dc.subject.keywordPlus | COMPLICATIONS | - |
dc.subject.keywordPlus | VILDAGLIPTIN | - |
dc.subject.keywordPlus | INFLAMMATION | - |
dc.subject.keywordPlus | GLIMEPIRIDE | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.